Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maridebart cafraglutide (AMG 133) in obesity and overweight with or without type 2 diabetes
NCT05669599Phase 2Completed
- Sponsor
- Amgen
- Start
- Jan 2023
- Primary completion
- Oct 2024
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of maridebart cafraglutide in obesity, sponsored by Amgen. Started Jan 2023; status: completed.
02
Drugs
maridebart cafraglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05669599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05669599.